Luteinising hormone is produced in the pituitary gland and stimulates ovulation and the production of oestrogen. LHRH agonists are molecules which mimic the action of luteinising Hormone by binding to the same receptors within the pituitary gland and thereby block the signal for ovarian production of oestrogen, which is known to stimulate the growth of breast cancer.
Professor Jack Cuzick, Cancer Research UK Centre for Epidemiology, Mathematics and Statistics, Wolfson Institute of Preventive Medicine, Queen Mary’s School of Medicine and Dentistry, University of London, UK and colleagues found that for hormone receptor-positive patients, LHRH agonists were as effective as chemotherapy treatment used in these trials.
Treatment with LHRH agonists combined with chemotherapy or tamoxifen gave an additional benefit, reducing recurrence of breast cancer by nearly 13% and death after recurrence by 15%. However the combined treatments only showed the additional benefit in women under 40. LHRH agonists were ineffective for hormone receptor-negative tumours.
The researchers did a meta-analysis (a study which combines results from previous trials) of 16 trials and obtained data for 11,906 premenopausal women with early breast cancer.
The authors conclude: “The results of our analysis show that LHRH agonists provide an effective additional class of agents for the treatment of premenopausal women with hormone-sensitive breast cancer.”
In an accompanying Comment, Drs Nicholas Wilcken and Martin Stockler, Department of Medical Oncology, Westmead and Napean Hosptials and University of Sydney, NSW, Australia and NHMRC Clinical Trials Centre, University of Sydney and Sydney Cancer Centre, Royal Prince Alfred and Concord Hospitals, NSW, Australia, say: “In women with higher-risk disease, chemotherapy followed by tamoxifen should still be the standard approach, with the addition of an LHRH analogue a reasonable consideration for those who remain premenopausal.
“A century of research has taught us much about endocrine therapy for breast cancer, but the most important lessons about adjuvant ovarian suppression will be learnt over the next decade.”
Tony Kirby | alfa
NIH scientists describe potential antibody treatment for multidrug-resistant K. pneumoniae
14.03.2018 | NIH/National Institute of Allergy and Infectious Diseases
Researchers identify key step in viral replication
13.03.2018 | University of Pittsburgh Schools of the Health Sciences
A new scenario seeking to explain how Mars' putative oceans came and went over the last 4 billion years implies that the oceans formed several hundred million...
For the first time, an interdisciplinary team from the University of Basel has succeeded in integrating artificial organelles into the cells of live zebrafish embryos. This innovative approach using artificial organelles as cellular implants offers new potential in treating a range of diseases, as the authors report in an article published in Nature Communications.
In the cells of higher organisms, organelles such as the nucleus or mitochondria perform a range of complex functions necessary for life. In the networks of...
Animal photoreceptors capture light with photopigments. Researchers from the University of Göttingen have now discovered that these photopigments fulfill an...
On 15 March, the AWI research aeroplane Polar 5 will depart for Greenland. Concentrating on the furthest northeast region of the island, an international team...
The world’s second-largest ice shelf was the destination for a Polarstern expedition that ended in Punta Arenas, Chile on 14th March 2018. Oceanographers from...
19.03.2018 | Event News
16.03.2018 | Event News
13.03.2018 | Event News
20.03.2018 | Physics and Astronomy
20.03.2018 | Physics and Astronomy
20.03.2018 | Earth Sciences